BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) – Equities researchers at HC Wainwright boosted their FY2024 earnings estimates for shares of BriaCell Therapeutics in a research report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.80) per share for the year, up from their prior estimate of ($1.39). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.52) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.12) EPS.
BriaCell Therapeutics Stock Performance
Shares of BCTX opened at $0.68 on Monday. The business’s fifty day moving average is $0.69 and its 200-day moving average is $1.49. The firm has a market cap of $12.47 million, a price-to-earnings ratio of -0.55 and a beta of 1.31. BriaCell Therapeutics has a 52-week low of $0.46 and a 52-week high of $6.36.
Institutional Investors Weigh In On BriaCell Therapeutics
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- The Average 401k Balance by Age Explained
- Market Cap Calculator: How to Calculate Market Cap
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.